U.S. Places Big H1N1 Vaccine Order With Australia’s CSL
This article was originally published in PharmAsia News
Australia's CSL has received a $142 million order for H1N1 flu vaccine expected to be ready for inoculations in October. The order from the United States, where 12 deaths have been attributed to the disease, includes U.S. funding for clinical trials for the Novel A version of the disease in bulk form. CSL received an order for 10 million doses from the Australian government just days before. (Click here for more
You may also be interested in...
CSL CEO Brian McNamee On Being Australia’s Only Homegrown MNC: An Interview With PharmAsia News (Part 1 of 2)
Australia's only homegrown multinational company in the pharmaceutical sector, CSL is at the forefront of producing a novel A H1N1 influenza vaccine, having signed a $180 million contract with U.S. Dept of Health and Human Services to provide the vaccine antigen in bulk form. CSL is also the originator of Merck's HPV vaccine Gardasil. CEO Brian McNamee talked with PharmAsia News' Australia bureau about CSL's operations at home and abroad.
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.